Acute myeloid leukemia (AML), also called acute myelogenous leukemia and acute nonlymphocytic leukemia, is a cancer of the blood and bone marrow. It is the most common type of acute leukemia in adults. AML progresses rapidly, with myeloid cells interfering with the production of normal white blood cells, red blood cells and platelets.
Currently the AML sphere constitutes a robust pipeline with more than 250+ drugs under different phases of development. Even along with the presence of so many therapeutic drugs, there is still need of targeted palliative care interventions and therapies with therapies with lower toxicity and better efficacy.
DelveInsight offers a new addition to its newsletter edition that pivots on the AML market. The newsletter provides a complete picture of the AML market landscape, ongoing clinical trials, and pipeline therapies expected to transform the AML market in the coming decade. Dive deep into rich insights of AML epidemiological insights, current treatment therapies, details of the latest news and happenings, mergers &amp; collaborations, major pharmaceuticals involved, licensing deals along with events, and top-level conferences.
Keen about what is in store for the AML market and how pharma companies are working to push the drug development? Download our Newsletter by simply filling up the form on the right.
Subscribe to our mailing list and stay informed about all the recent breakthroughs in the AML market.

Acute myeloid leukemia (AML), also called acute myelogenous leukemia and acute nonlymphocytic leukemia, is a cancer of the blood and bone marrow. It is the most common type of acute leukemia in adults. AML progresses rapidly, with myeloid cells interfering with the production of normal white blood cells, red blood cells and platelets.

Acute Myeloid Leukemia

The Acute Myeloid Leukemia newsletter provides a complete picture of the AML market landscape, ongoing clinical trials, and pipeline therapies expected to transform the AML market in the coming decade.